Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimecrolimus versus triamcinolone for epidermal barrier restoration in adult atopic dermatitis
2007-003106-99Phase 2Active
- Sponsor
- Christian-Albrechts-Universität zu Kiel
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pimecrolimus and triamcinolone acetonide in atopic dermatitis (AD) (2 arms), sponsored by Christian-Albrechts-Universität zu Kiel. Primary endpoints: Normalization of physiological lamellar bodies and Percentage of physiological lamellar bodies. Started Aug 2007; status: active.
02
Drugs
pimecrolimustriamcinolone acetonide
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2007-003106-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003106-99.